BEIJING, China: CanSino Biologics has announced that its recently developed COVID-19 vaccine has been approved by China’s drug regulator for emergency use as a booster.
In a filing, the company said the inhaled version of its COVID-19 vaccine has obtained approval from the National Medical Products Administration.
“The approval will have a positive impact on the company’s performance if the vaccine is subsequently purchased and used by relevant government agencies,” CanSino said.
However, the new vaccine will face fierce competition from other vaccines in China that have also obtained government approval or are in clinical trials, the company said.
Also in China, Livzon Pharmaceutical Group said the government has granted emergency use for its COVID-19 vaccine as a booster, one of just two new products that gained approval in the country in the past year.
However, since additional administrative approvals are still needed, Cansino stressed that it was not certain when its vaccine would enter the market, and sales would depend on China’s vaccination rate, as well as the local and international COVID-19 situation.
On 3rd September, Mainland China reported 1,848 new coronavirus cases, compared with 1,988 new cases one day earlier.
